Research Focus 研究方向為探討癌症因子機制及治療抗性之分子病理機制，並找尋癌症標誌並研發治療標誌與藥物。研究方向包含 - 癌症相關分子鑑定,透過細胞、分子生物與基因體學方式鑑定出癌症相關分子如 CHES1, DSG3,Cyr61等分子參與調控癌化過程。 - 尋找循環腫瘤標誌，運用分析腫瘤微環境分泌性蛋白質及分析循環腫瘤細胞之分子特性以發展相關癌症標誌 - 藥物開發與鑑定，透過整合疾病、基因、藥物之綜和概念來尋找影響放療抗性治療標靶與相關藥物。 透過研究癌症標誌與潛在治療藥物之間關連性提供學理知識，期望對於未來臨床診斷、治療應用之價值
Selected Publications Kuo JR, Shang HS, Ho CT, Lai KG, Liu TZ, Chen YJ*, Chiou JF. Cisplatin-induced regulation of signal transduction pathways and transcription factors in p53-mutated subclone variants of hepatoma cells: potential application for therapeutic targeting. Oncology Letters 2015. Chen CY, Lin YS, Chen CL, Chao PZ, Chiou JF, Kuo CC, Lee FP, Lin YF, Sung YH, Lin YT, Li CF, Chen YJ*, Chen CH*. Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma. Oncotarget 2015 Jul 9. Lee LY, Chen YJ*, Lu YC, Liao CT, Chen IH, Chang JT, Huang YC, Chen WH, Huang CC, Tsai CY, Cheng AJ. Fascin is a circulating tumor marker for head and neck cancer as determined by a proteomic analysis of interstitial fluid from the tumor microenvironment. Clin Chem Lab Med. 2015 Mar 10. Lu YC, Chang JT, Huang YC, Huang CC, Chen WH, Lee LY, Huang BS, Chen YJ, Li HF, Cheng AJ. Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clin Biochem. 2015 Feb;48(3):115-21 Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li YL, HM Wang, JT Chang, Cheng AJ. Grp78 as a therapeutic target for refractory head–neck cancer with CD24-CD44+ stemness phenotype. Cancer Gene Therapy. 2013 Nov;20(11):606-15. Chen YJ, Lee LY, Chao YK, Chang Joseph T., Lu YC, Li HF, Chiu CC, Li YC, Li YL, Chiou JF, Cheng AJ. DSG3 facilitates cancer cell growth and invasion through DSG3- plakoglobin - TCF/LEF -myc/cyclin D1/MMP signaling pathway. PLoS One. 2013 May 30;8(5):e64088. Lu YC, Chen YJ, Wang HM, Tsai CY, Chen WH, Huang YC, Fan KH, Tsai CN, Huang SF, Kang CJ, Chang JT, Cheng AJ. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila). 2012 Apr;5(4):665-74.